Trevi Therapeutics (TRVI) Aktievy
Trevi Therapeutics, Inc. är ett biofarmaceutiskt företag i klinisk fas som utvecklar och kommersialiserar läkemedel för behandling av kronisk hosta hos patienter med idiopatisk lungfibros (IPF) och interstitiell lungsjukdom utan IPF, samt refraktär kronisk hosta. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 1/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
TRVI Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Trevi Therapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$14.13 |
| 52 veckors högsta | US$16.12 |
| 52 veckors lägsta | US$5.38 |
| Beta | 1.08 |
| 1 månads förändring | -1.94% |
| 3 månaders förändring | 25.27% |
| 1 års förändring | 124.64% |
| 3 års förändring | 481.48% |
| 5 års förändring | 563.38% |
| Förändring sedan börsintroduktionen | 79.09% |
Senaste nyheter och uppdateringar
Recent updates
Trevi Therapeutics: Late-Stage Transition Meets Execution Risk
Summary Trevi Therapeutics is transitioning to a late-stage biotech, prioritizing Haduvio for IPF-related chronic cough as its lead indication. TRVI's strong cash position, bolstered by a $150M stock offering, funds operations into 2028 and reduces near-term financing risk. Haduvio's Phase 3 trials in IPF chronic cough, with quantifiable endpoints and safety focus, are the pivotal near-term catalysts for TRVI. Despite a premium valuation (P/B 10.2x–16.3x), TRVI's upside relies on successful late-stage execution; I recommend holding until Phase 3 data. Read the full article on Seeking Alpha
Chronic Cough Trials And Focused Pulmonologist Reach Will Support Long Term Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio for chronic cough conditions associated with fibrotic lung diseases and refractory chronic cough. What are the underlying business or industry changes driving this perspective?
Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio, an extended release formulation of nalbuphine, for multiple chronic cough indications where there are currently no FDA approved therapies. What are the underlying business or industry changes driving this perspective?We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...Trevi adds 19% on full data set from mid-stage cough study
Clinical-stage biopharma, Trevi Therapeutics, Inc. (NASDAQ:TRVI) gained 19% pre-market Monday after the company announced complete data from its Phase 2 trial for lead asset Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) U.K.-based CANAL study was designed to compare Haduvio, an oral extended-release formulation of pain therapy nalbuphine, against placebo in terms of the mean daytime cough frequency at Day 22 as the primary endpoint, as measured by an objective cough monitor. The full set of subjects (N=38) reached the primary endpoint with statistical significance indicating a 52.5% change in daytime cough frequency for Haduvio compared to placebo (p<0.0001). The reduction of cough frequency stood at ~76.1% and 25.3% in Haduvio and placebo arms, respectively. The safety profile was in line with data from previous studies for the treatment, and two adverse events were found to be unrelated to the experimental therapy. TRVI expects to start the next trial for this indication in H1 2023. A previous readout from 26 patients in the CANAL trial indicated a 52% placebo-adjusted reduction in daytime cough events for Haduvio.Trevi Therapeutics: Moving Forward
Summary Today, we put Busted IPO Trevi Therapeutics in the spotlight for the first time ever. The company's primary drug candidate Haduvio is moving towards late-stage development as a treatment for prurigo nodularis as well as chronic cough in adults with idiopathic pulmonary fibrosis. An investment analysis follows in the paragraphs below. "It's not unpatriotic to denounce an injustice committed on our behalf, perhaps it's the most patriotic thing we can do."― E.A. Bucchianeri Today, we take our first look at Trevi Therapeutics Inc. (TRVI). The small biopharma firm came public just over three years ago and is deep in Busted IPO territory even with a nice rebound in the shares so far in 2022. What lies ahead for Trevi Therapeutics? An analysis follows below. Seeking Alpha Company Overview Trevi Therapeutics is a clinical-stage biopharmaceutical company based out of New Haven, CT. The company focuses on the development of medicines to treat serious neurologically mediated conditions. Its primary asset in development is Haduvio which is an oral extended-release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. Haduvio has a dual mechanism of action by acting as both an antagonist (blocker) to the body's mu opioid receptor and as an agonist (activator) to the kappa opioid receptor. March Company Presentation This candidate is currently being evaluating for the treatment of prurigo nodularis or PN and chronic cough in adults with idiopathic pulmonary fibrosis or IPF. Chronic cough represents a significant unmet need for IPF patients, as the majority of these patients report this cough as one of their most bothersome aspects of their disease. March Company Presentation Haduvio or Nalbuphine Extended Release [ER] has also been granted Fast Track designation by the FDA for the treatment of itch in patients with prurigo nodularis. In 2011, Endo Pharmaceuticals partnered with Trevi to develop and market compounds incorporating nalbuphine hydrochloride. The stock currently trades just over three bucks a share and sports an approximate market capitalization of $140 million. Pipeline Developments Company Website The stock got a bump in late June 29th when the company disclosed that Haduvio had met key goals in a Phase 2b/3 'PRISM' study for patients with prurigo nodularis. 25% met the primary efficacy endpoint, a clinical measure called 4-point reduction in the Worst Itch - Numerical Rating Scale compared to just 14% of the placebo group. March Company Presentation Patients are currently completing the one-year open-label extension study, which should be over in January. The company is in the process of having an end of Phase 2 meeting with the FDA to discuss the data, next steps and the design for a registrational study that could lead to approval dependent on results. The company would like to do a six-month study with three treatment groups. March Company Presentation Four months before, interim data from a Phase 2 trial evaluating Haduvio to treat IPF suffering from chronic cough found a 52% placebo-adjusted reduction in daytime cough events and the compound was well tolerated. Full results should be out by the end of this quarter. A meeting with the FDA should happen to soon to move this effort to the next stage of development. The company believes this will begin in the first half of 2023. Haduvio could have other potential indications in this category (see above) for other indications. March Company Presentation Analyst Commentary & Balance Sheet Aegis Capital, Oppenheimer and Needham have all reiterated Buy ratings on TRVI over the past four months. All have identical $10 price targets on the stock.Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Aktieägarnas avkastning
| TRVI | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | 5.2% | 5.3% | 1.1% |
| 1Y | 124.6% | 44.3% | 28.7% |
Avkastning vs industri: TRVI översteg US Pharmaceuticals branschen som gav 44.3 % under det senaste året.
Avkastning vs Marknaden: TRVI översteg US marknaden som gav 28.7 % under det senaste året.
Prisvolatilitet
| TRVI volatility | |
|---|---|
| TRVI Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: TRVI har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: TRVI s veckovolatilitet ( 8% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2011 | 34 | Jennifer Good | www.trevitherapeutics.com |
Trevi Therapeutics, Inc. är ett biofarmaceutiskt företag i klinisk fas som utvecklar och kommersialiserar läkemedel för behandling av kronisk hosta hos patienter med idiopatisk lungfibros (IPF) och interstitiell lungsjukdom utan IPF, samt refraktär kronisk hosta. Företaget utvecklar Haduvio, en oral nalbuphinformulering med förlängd frisättning, som genomgår en klinisk fas 2b-studie med nalbuphin ER för behandling av kronisk hosta hos patienter med IPF, och en klinisk fas 2a-studie hos patienter med refraktär kronisk hosta. Trevi Therapeutics, Inc. har ett licensavtal med Keenova Therapeutics plc för utveckling och kommersialisering av produkter som innehåller nalbuphinhydroklorid i olika beredningsformer.
Trevi Therapeutics, Inc. Sammanfattning av grunderna
| TRVI grundläggande statistik | |
|---|---|
| Börsvärde | US$2.01b |
| Vinst(TTM) | -US$45.61m |
| Intäkter(TTM) | n/a |
Är TRVI övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| TRVI resultaträkning (TTM) | |
|---|---|
| Intäkter | US$0 |
| Kostnad för intäkter | US$0 |
| Bruttovinst | US$0 |
| Övriga kostnader | US$45.61m |
| Intäkter | -US$45.61m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.32 |
| Bruttomarginal | 0.00% |
| Nettovinstmarginal | 0.00% |
| Skuld/egenkapitalförhållande | 0% |
Hur har TRVI utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/25 12:44 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Trevi Therapeutics, Inc. bevakas av 16 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |